What WuXi Biologics Buyers Were Betting On

Simply Wall St.10-24 13:38

WuXi Biologics (Cayman) spent this period racking up concrete wins, including fresh FDA and ANVISA approvals that opened the door to commercial supply of complex therapies for autoimmune disease and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2677901859?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/9551728-choice2-card/1789016329041","is_english":true,"pubTime":"2026-10-24 13:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2677901859","market":"nz","top_or_hot":-1,"title":"What WuXi Biologics Buyers Were Betting On","media":"Simply Wall St.","content":"<div>\n<p>WuXi Biologics (Cayman) spent this period racking up concrete wins, including fresh FDA and ANVISA approvals that opened the door to commercial supply of complex therapies for autoimmune disease and ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/what-wuxi-biologics-buyers-were-betting-on-1\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What WuXi Biologics Buyers Were Betting On</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat WuXi Biologics Buyers Were Betting On\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-24 13:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/what-wuxi-biologics-buyers-were-betting-on-1><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>WuXi Biologics (Cayman) spent this period racking up concrete wins, including fresh FDA and ANVISA approvals that opened the door to commercial supply of complex therapies for autoimmune disease and ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/what-wuxi-biologics-buyers-were-betting-on-1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0823426480.USD","symbol_name":"法巴中国股票经典Dis","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/what-wuxi-biologics-buyers-were-betting-on-1","article_id":"2677901859","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/9551728-choice2-card/1789016329041"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/what-wuxi-biologics-buyers-were-betting-on-1","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2677901859","pubTimestamp":1792820328,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"WuXi Biologics (Cayman) spent this period racking up concrete wins, including fresh FDA and ANVISA approvals that opened the door to commercial supply of complex therapies for autoimmune disease and cancer. For WuXi Biologics (Cayman) shareholders, the return from the start of the year was 40.7%, including dividends. If you were deciding on 1 January whether to buy, what exactly would you have needed to believe about future projects and margins to view that outcome as justified?\nThis theme...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0823426480.USD":"法巴中国股票经典Dis","LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","LU0823426308.USD":"法巴中国股票基金","BK1521":"挪威政府全球养老基金持仓","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","02269":"药明生物","LU0359201612.USD":"贝莱德中国基金A2","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU0051755006.USD":"摩根大通中国A (dist)","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU0320764243.SGD":"FTIF - Templeton Emerging Markets A Acc SGD","BK1576":"医药外包概念","LU1720050803.USD":"安联全方位中国股票基金","KURE":"KraneShares MSCI All China Health Care Index ETF","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0052750758.USD":"富兰克林中国基金A Acc","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU0128522744.USD":"TEMPLETON EMERGING MARKETS \"A\" ACC","IE00BFMHRM44.USD":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","LU3063872942.SGD":"FULLERTON LUX FUNDS ASIA EQUITIES \"I\" (SGD) ACC","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","LU0708995153.HKD":"TEMPLETON EMERGING MARKETS \"A\" (HKD) ACC","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","LU2399975544.HKD":"ALLIANZ ALL CHINA EQUITY \"AT\" (HKD) ACC","LU0140636845.USD":"施罗德大中华区股票A Acc","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","LU0029874905.USD":"TEMPLETON EMERGING MARKETS \"A\" INC"},"translate_title":"药明生物买家押注什么","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KURE":0.6,"02269":0.9},"content_text":"WuXi Biologics (Cayman) spent this period racking up concrete wins, including fresh FDA and ANVISA approvals that opened the door to commercial supply of complex therapies for autoimmune disease and cancer. For WuXi Biologics (Cayman) shareholders, the return from the start of the year was 40.7%, including dividends. If you were deciding on 1 January whether to buy, what exactly would you have needed to believe about future projects and margins to view that outcome as justified? This theme extends beyond WuXi Biologics (Cayman). See which of 124 healthcare AI stocks may still merit a closer look. AdvertisementThe Argument You Would Have Been Weighing Up On WuXi Biologics (Cayman) The shares cost HK$31.44 at the start, and WuXi Biologics (Cayman) sat between two very different but plausible stories about where the business might head next. On the optimistic view, a Fair Value of HK$37.16, as an implied price from the growth case, rested on revenue rising 15.8% a year with profit margin at 21.0% and a future P/E of 25.5x. The more cautious narrative pointed to a Fair Value of HK$20.16, built on concerns that dependence on Western clients and potential overcapacity could keep revenue growth nearer 10.7% and trim margins to 20.1%. SEHK:2269 Trailing 12-Month Earnings & Revenue History as at Oct 2026 What The Results Changed For WuXi Biologics (Cayman) The clearest new data point was H1 2026 revenue of C¥11,787.238m and net income of C¥2,439.813m, alongside a net margin that moved from 23.5% to 20.7%. That pattern, higher sales and profit but a thinner margin, leaned toward the cautious case that questioned how firmly WuXi Biologics (Cayman) could hold profitability. The useful takeaway is simple: when a story depends on margins, not just growth, keep checking whether profit as a share of revenue tracks the original claim. Apply the same test to any contract manufacturer that is expanding capacity on the promise of future operating leverage. What WuXi Biologics (Cayman)'s Price Already Assumes After A 41% Run WuXi Biologics (Cayman) now trades at HK$45.8 from the start of the year, and the selected Narrative’s Fair Value sits below that level. The argument does not question the backlog. It questions how much of that work turns into reported profit once currency swings and heavy global buildout are accounted for. A buyer today effectively has to believe that WuXi Biologics can translate its expanding CRDMO footprint into sustained high margin output and resilient returns. The Narrative asks how foreign exchange pressure and capital intensive capacity growth affect that assumption if funding or utilization wobble. \"The main thing that has to go right is that WuXi Biologics converts its large, complex CRDMO portfolio and expanding global capacity into sustained, high margin manufacturing and IP based revenue growth that more than offsets rising capex, foreign exchange headwinds and external funding pressures on biotech customers.\" Not everyone reads the same price the same way. → See the lower figure this Narrative lands on, and how it gets there Where WuXi Biologics Points Next WuXi Biologics focuses on manufacturing complex therapies at scale. That focus hints at a different kind of healthcare engine. Your autoimmune and oncology thesis often leans on one more ingredient. New medicines still need creators willing to fund discovery and long trials. Another large drug developer does that across diabetes, obesity, cancer and brain health. It spends heavily to move fresh treatments from early testing to market. Those therapies then rely on others, including players like WuXi Biologics, to reach patients globally. The open question is how value splits between the labs and the builders. One Narrative has already put a figure on it. → Uncover the company trading 14% below one Narrative's Fair Value This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if WuXi Biologics (Cayman) might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2677901859","isCrawlerRequest":true}